CINACALCET REMAINS EFFECTIVE IN PRIMARY HYPERPARATHYROIDISM AFTER 4 YEARS OF TREATMENT
Department of Endocrinology and Nutrition - Hospital Virgen de la Salud, Toledo (Spain)

INTRODUCTION
Cinacalcet is an oral calcimimetic indicated in treatment of primary hyperparathyroidism in patients who are unable to undergo parathyroidectomy: do not accept surgery, there is failure of previous surgery or serious comorbidity that makes surgery impossible.

METHODS
Descriptive study that includes 9 patients with primary hyperparathyroidism who have completed at least 48 months of treatment with cinacalcet (7 patients refusal to parathyroidectomy and 2 surgery not possible due to comorbidities). We recorded clinical and biochemical data at baseline and after 3, 6, 12, 24 and 48 months of treatment.

RESULTS
Results of Ca, P and PTH at baseline, and at 12 and 48 months of treatment

Table 1: Basal characteristics

| Age at diagnosis (Years) | 76 ±6.4 |
| Femaless                  | 88.9 %  |
| Time of treatment (months)| 49      |

No further variation was observed after 24 and 48 months compared to 12 months follow up except for an increase in PTH to baseline levels.

Normocalcemia (Ca < 10.2 mg/dl) was achieved in 55.7% patients

Usually the medication was well-tolerated and no serious adverse events were observed

CONCLUSION
Hypercalcemia is rapidly improved by Cinacalcet and remains stable after 48 months follow-up. Cinacalcet is an effective and safe alternative in non-surgical treatment of primary hyperparathyroidism in case of surgical contraindications.